Takeda Pharmaceutical Company Limited
TAKHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Jul 18, 2026
Scan Results
Daily timeframePart of the healthcare sector, Takeda Pharmaceutical Company Limited (TAK) is listed under Drug Manufacturers - Specialty & Generic. The company carries a $54.77B market cap, placing it firmly in the large-cap category. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.
Market Cap
$54.77B
Beta
0.09
P/E (TTM)
—
P/E (Fwd)
32.36
EPS (TTM)
$-0.31
EPS (Fwd)
$0.53
ROE
-2.1%
ROA
2.5%
Cash
$595.05B
Total Debt
$5.48T
Free CF
$672.78B
52W Change
18.9%
Annual Financials
Cash vs Debt
Takeda Pharmaceutical Company Limited carries $5.48T in total debt against $595.05B in cash reserves — debt is roughly 9.2x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $672.78B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -2.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 2.5% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $4.03T to $4.51T.
The relatively low beta of 0.09 suggests TAK is a less volatile holding compared to the broader index. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. No single metric tells the full story. Reviewing TAK's risk profile alongside its fundamentals and technical indicators provides a more complete picture.